β-adrenergic signaling modulates key signaling pathways that are important for tumor-promoting processes, and numerous mechanisms of action have been elucidated. Preclinical studies have demonstrated that β-adrenergic antagonists, or β-blockers, can block multiple fundamental biologic processes underlying the progression and metastasis of tumors, including the inhibition of cell proliferation, ...

OBJECTIVE To clarify whether any particular β blocker is superior in patients with heart failure and reduced ejection fraction or whether the benefits of these agents are mainly due to a class effect. DESIGN Systematic review and network meta-analysis of efficacy of different β blockers in heart failure. DATA SOURCES CINAHL(1982-2011), Cochrane Collaboration Central Register of Controlled T...

AIMS To assess whether the use of beta-blockers influences mortality and the incidence of major cardiovascular events in patients with diabetes and coronary heart disease (CHD). MATERIALS AND METHODS Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, we performed Cox proportional hazards analysis to assess the effects of β-blockers on all-cause mortality ...

Cancer is one of the leading causes death in world. Researchers keep attempting to develop therapy modalities decrease mortality and morbidity cancer patients by trying comprehend effect sympathetic nerves (through catecholamine adrenergic receptors) development. Catecholamine activation β-adrenergic receptors (β1-AR, β2-AR, β3-AR) may influence cytokine immunity system, initiate tumorigenesis,...

M e t h o d s Data sources: PubMed and the Cochrane Library. Study selection and assessment: Randomized controlled trials (RCTs) that compared β-blockers as first-line treatment with placebo, no treatment, or other antihypertensive drugs in patients with primary hypertension, and evaluated all-cause mortality, cardiovascular morbidity, or both. Subgroup analyses were conducted for nonatenolol β...

OBJECTIVE To examine the effect of β blockers in the management of chronic obstructive pulmonary disease (COPD), assessing their effect on mortality, hospital admissions, and exacerbations of COPD when added to established treatment for COPD. DESIGN Retrospective cohort study using a disease specific database of COPD patients (TARDIS) linked to the Scottish morbidity records of acute hospital...

β blockers are useful in managing angina and reducing mortality after myocardial infarction and in heart failure. They probably reduce cardiovascular events in high risk surgery and retard the progression of atherosclerosis. In younger patients, β blockers should remain first line antihypertensives, together with diuretics, calcium channel blockers, angiotensin converting enzymes, and adrenergi...

β-Adrenergic receptors (β-ARs) are G protein-coupled involved in important physiological and pathological processes related to blood pressure cardiac activity. The inhibition of β1-ARs could be beneficial myocardial hypertrophy, ischemia failure. Several carbazole-based compounds have been described as promising β-blockers. Herein, we investigate the capability a carbazole derivative three simp...

OBJECTIVE Although β-blockers are an established therapy in heart failure (HF) guidelines, including for patients with chronic obstructive pulmonary disease (COPD), there remain concerns regarding bronchoconstriction even with cardioselective β-blockers. We wished to assess the real-life use of β-blockers for patients with HF and comorbid COPD. METHODS We evaluated data from the Optimum Patie...

The role of β-adrenoceptor antagonists (β-blockers) in cardiovascular therapy has been subject to diverse trends and changes over the decades. With the advent of a wide variety of excellent drugs for the treatment of antihypertension, β-blockers have been relegated from the first-line treatment of essential hypertension. However, they remain the drugs of first choice in recommendations from the...